Related Experiment Video
Updated: Jul 6, 2025

05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.6K
SADR: Self-Supervised Graph Learning With Adaptive Denoising for Drug Repositioning.
Summary
We developed SADR, a novel self-supervised graph learning model for drug repositioning. It effectively handles sparse data and noise, improving prediction accuracy for identifying new drug-disease associations.
Area of Science:
- Computational biology
- Drug discovery
- Bioinformatics
Background:
- Traditional drug development is costly and time-intensive.
- Drug repositioning offers a faster, more cost-effective alternative.
- Graph representation learning methods show promise for drug repositioning but struggle with sparse and noisy data.
Purpose of the Study:
- To propose a robust drug repositioning model that overcomes limitations of existing graph-based methods.
- To enhance prediction accuracy in sparse datasets and improve robustness against noise.
Main Methods:
- Developed SADR (Self-supervised graph learning with Adaptive Denoising) model.
- Employed data augmentation and contrastive learning for node feature representation.
- Integrated an adaptive denoising training (ADT) component to mitigate noise impact.
Main Results:
- SADR demonstrated superior prediction accuracy over baseline models across three datasets.
- The model effectively addresses challenges posed by data sparsity and noise.
- Identified top 10 potential approved drugs for treating two specific diseases.
Conclusions:
- SADR offers a robust and effective approach for drug repositioning.
- The model's ability to handle data imperfections enhances its utility in drug discovery.
- SADR successfully identifies novel drug candidates for disease treatment.
Related Concept Videos
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug-Receptor Interaction: Antagonist
2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726
Pharmacovigilance
835
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
835
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K

